FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and chemical-pharmaceutical industry. The group of inventions refers to pharmaceutical composition for local application and containing an active ingredient presented by superoxide dismutase as a part of cross-linked methoxy-poly(ethylene glycol)-poly(L-lysine) block copolymer nanoparticles, as well as to a method of treating inflammatory eye diseases using the given pharmaceutical compositions. The active ingredient content in the composition makes 50-500 kUnit/ml. The composition can be presented in the form of eye drops or a spray. In addition, the composition contain antibiotics, steroids, adrenoreceptor blocking agents, macro- and microelements, and vitamins.
EFFECT: group of inventions provides the intensified and prolonged anti-inflammatory action of superoxide dismutase on the eye diseases related to inflammatory processes.
7 cl, 1 dwg
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION FOR TREATING EYE DISEASES ACCOMPANIED BY OXIDATIVE STRESS, AND A METHOD FOR USE THEREOF | 2018 |
|
RU2694226C1 |
METHOD OF TREATING EYE DISEASES ACCOMPANIED BY OXIDATIVE STRESS | 2014 |
|
RU2577236C1 |
AGENT FOR REDUCING INTRAOCULAR PRESSURE AND METHOD OF USE THEREOF | 2022 |
|
RU2815996C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING EYE INFECTIONS P. Aeruginosa CONTAINING RECOMBINANT LYSOZYME | 2011 |
|
RU2548803C2 |
COMPOSITION WHICH REDUCES OXIDATIVE STRESS IN EYE | 2019 |
|
RU2733928C2 |
METHOD FOR TREATING UVEITIS IN CHILDREN | 1999 |
|
RU2185193C2 |
COMPOUNDS FOR TREATING/PREVENTING INFLAMMATORY OPHTHALMIC DISEASES | 2011 |
|
RU2582609C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING EYE DISEASES RELATED TO EYE TISSUE METABOLIC DISEASE AND INFLAMMATORY EYE TISSUE INJURY | 2013 |
|
RU2521337C1 |
PHOSPHOLIPID NANOPARTICLE INDOMETACIN APPLICABLE IN OPHTHALMOLOGY | 2011 |
|
RU2456979C1 |
METHOD FOR TREATMENT AND PROPHYLAXIS OF OPHTHALMIC DISEASE ASSOCIATED WITH EYE TISSUE ISCHEMIA | 2004 |
|
RU2268722C2 |
Authors
Dates
2014-02-27—Published
2012-07-19—Filed